Cardiac muscle

A New Study Suggests Energy4Life’s Bioenergetic Wearable Device May Have Positive Effects on Cellular Membrane

Retrieved on: 
Mercoledì, Marzo 22, 2023
Wearables, Mobile Technology, Manufacturing, Biometrics, Other Technology, Research, Medical Devices, Hardware, Data Management, Fitness & Nutrition, Consumer Electronics, Science, Technology, Mobile, Wireless, General Health, Biotechnology, Alternative Medicine, Health, Engineering, DNA, Acupuncture, Field line, University, Photon, Mitochondrion, GEM, Sleep, ATP, Ageing, Light, Physiology, Multimedia, Emotion, Cardiac muscle, Cell, San Diego, Stem cell, Skeletal muscle, Fatigue, Patient, Sound, Physics, Viral, Medicine, Massey, Nursing, Consumer electronics, Medical device, Medical imaging

A recent study by researchers at the University of California at San Diego, found that a bioenergetic wearable device delivering biological information to the body using photons, has positive effects on the physiology of live cell cultures.

Key Points: 
  • A recent study by researchers at the University of California at San Diego, found that a bioenergetic wearable device delivering biological information to the body using photons, has positive effects on the physiology of live cell cultures.
  • View the full release here: https://www.businesswire.com/news/home/20230320005633/en/
    A cutting-edge technology, developed and created by Energy4Life, bioenergetic wearable devices use digitized biological information to help restore the body’s energy.
  • “Our bioenergetic wearables are designed to communicate directly to the body, thus triggering its self-repair system,” said Harry Massey, founder and CEO of Energy4Life.
  • Further studies are being conducted on how the wearable may aid energy and emotional management, reduce stress, and improve sleep and energy.

A NEW STUDY SUGGESTS ENERGY4LIFE'S BIOENERGETIC WEARABLE DEVICE MAY HAVE POSITIVE EFFECTS ON CELLULAR MEMBRANE

Retrieved on: 
Mercoledì, Marzo 22, 2023
DNA, Acupuncture, Field line, University, Photon, Mitochondrion, GEM, Sleep, ATP, Ageing, Light, Physiology, Research, Emotion, Cardiac muscle, Cell, San Diego, Stem cell, NES, Skeletal muscle, Fatigue, Oxidative stress, Patient, Sound, Physics, Viral, Medical research, PARK, Medicine, Massey, Vaccine, Nursing, Consumer electronics, Medical device, Medical imaging

PARK CITY, Utah, March 22, 2023 /PRNewswire/ -- A recent study by researchers at the University of California at San Diego, found that a bioenergetic wearable device delivering biological information to the body using photons, has positive effects on the physiology of live cell cultures. This study has found these results may lead to improved energy levels and sleep quality, reduce stress, and help people better manage their emotions.

Key Points: 
  • This study has found these results may lead to improved energy levels and sleep quality, reduce stress, and help people better manage their emotions.
  • A cutting-edge technology, developed and created by Energy4Life, bioenergetic wearable devices use digitized biological information to help restore the body's energy.
  • "Our bioenergetic wearables are designed to communicate directly to the body, thus triggering its self-repair system", said Harry Massey founder and CEO of Energy4Life.
  • This equipment includes the NES Health miHealth device and the GEM wearable, a new device slated for release in late 2023 by Massey's newest company, Energy4Life.

Solid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases

Retrieved on: 
Martedì, Gennaio 10, 2023
IND, Disease, Spinal cord, CFA, Tissue, Heart, AAV, Duchenne muscular dystrophy, FA, HSV, Solid, Conference, Capsid, Cerebellum, Tropism, NHP, Investigational New Drug, Duchenne, Research, Heart failure, Liver, FXN, Cardiac muscle, Investment, BAG3, Pharmaceutical industry, Management, Vaccine, Agriculture, Hospital

CHARLESTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today outlined its strategic priorities for 2023. These announcements are being made in advance of Solid’s presentation at the 41st Annual J.P. Morgan Healthcare Conference scheduled for January 12 at 9:00 am PT.

Key Points: 
  • “The Solid leadership team has deep expertise in precision genetic medicine, and our diversified pipeline targets diseases with high unmet need, strong scientific rationale, and significant commercial potential.
  • Solid remains focused on developing next-generation AAV capsid libraries with two strategies designed to enhance cardiac and skeletal muscle tropism.
  • Clear mechanistic rationale between genetic BAG3 insufficiency and myofilament damage, poor contraction and heart failure
    Solid’s construct candidates utilize the AAVrh74 capsid and cardiac specific promoter.
  • In early nonclinical studies, the specific capsid and cardiac-specific promoter combination increased cardiac expression while reducing expression in the liver.

$2.6 Billion Worldwide Mesenchymal Stem Cells Industry to 2029 - by Product & Service, Type, Source of Isolation, Indication, Application and Region - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Dicembre 16, 2022
Health, Stem Cells, Cell, Cardiovascular disease, Product-service system, Regenerative medicine, Fibroblast, Stem cell, Cancer, Bone marrow, Cartilage, Environment, Conditional sentence, Tissue engineering, Tendon, Cardiac muscle, Drug development, Lung, Fibrosis, Research, Apoptosis, MSC, Endothelium, Institute of Liver and Biliary Sciences, Graft-versus-host disease, Fine chemical, Medical imaging

However, lack of standardization and regulation of delivery of stem cell system is expected to limit the market growth.

Key Points: 
  • However, lack of standardization and regulation of delivery of stem cell system is expected to limit the market growth.
  • Based on product & service, the market is bifurcated into products and services.
  • In 2021, the allogenic segment accounted for the highest revenue share owing to the use of allogeneic mesenchymal stem cells in clinical settings has a good safety profile.
  • Based on application, the market is segregated into tissue engineering, disease modeling, drug development & discovery, toxicology studies, stem cell banking, and others.

Maze Therapeutics Announces Completion of Phase 1 First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease

Retrieved on: 
Giovedì, Dicembre 15, 2022
Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, GAA, Clinical trial, PD, Glycogen storage disease type II, Data science, Cardiac muscle, Safety, Pharmacokinetics, Pompe, Glycogen, Bridge, Gene, Research, HIV disease progression rates, PK, Therapy, Compass, Tissue, Patient, Pharmaceutical industry, Maze

MZE001, an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup, is being evaluated for the potential oral treatment of patients with Pompe disease.

Key Points: 
  • MZE001, an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup, is being evaluated for the potential oral treatment of patients with Pompe disease.
  • Based on these findings, Maze plans to initiate a Phase 2 clinical trial of MZE001 in 2023.
  • We look forward to carrying this program forward into a Phase 2 clinical trial in patients with Pompe disease who need improved treatment options for their disease.
  • MZE001 is currently being evaluated for the potential oral treatment of patients with Pompe disease and potentially other glycogen storage disorders.

Impulse Dynamics Announces 100th Implant Milestone in China for CCM® Therapy

Retrieved on: 
Mercoledì, Novembre 16, 2022
Tao, Marketing, Blood, Cardiac muscle, Heart, Muscle tissue, Medicine, Forward problem of electrocardiology, Heart rate, Chinese Academy of Medical Sciences COVID-19 vaccine, Safety, Physician, Patient, Heart failure, National Center for Health Research, Chinese Medical Doctor Association, MD, Mathematical optimization, CCM, News, Internal medicine, Chinese Academy of Fishery Sciences, Death, Degenerative disease, Research, Quality of life, Hope, Medicine in China, FDA, Medical device, Pharmaceutical industry

It is quite a coincidental milestone for us that the 10th patient implanted in our center also happened to be the 100th patient treated in China.

Key Points: 
  • It is quite a coincidental milestone for us that the 10th patient implanted in our center also happened to be the 100th patient treated in China.
  • I have paid very close attention to CCM therapy for more than 20 years now, but it wasnt until recently we could clinically apply this technology.
  • All the CCM patients in our center improved both symptomatically and on various objective indicators, which made both us and our patients very happy.
  • CCM therapy was approved in China late last year, and the first implant in the country was announced on November 1, 2021.

Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Novembre 10, 2022
Linda, GLOBE, Review, RNA transfection, Private Securities Litigation Reform Act, Organic acid, Protein, Intellectual property, Congress, PUL, Vaccine, U.S. Securities and Exchange Commission, Severe acute respiratory syndrome coronavirus 2, Exosome, Webcast, Research, Tissue, Cardiac muscle, COVID-19, Therapy, Drug discovery, NASDAQ, Muscle, ID, Safety, Duchenne muscular dystrophy, Goal, International, Company, WMS, Disease, Conference, Patient, Pivotal, DMD, Immunization, Data, Ownership, Security (finance), FDA, Pharmaceutical industry, Facebook

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • Additionally, the results support potential disease modifying outcomes and reinforce the long-term safety potential of CAP-1002 in patients with DMD.
  • Results were presented at a poster session at the World Muscle Society Congress (WMS) in Halifax, Nova Scotia, Canada on October 14, 2022.
  • Capricor Therapeutics, Inc. (NASDAQ: CAPR) biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases.
  • All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results

Retrieved on: 
Martedì, Novembre 8, 2022
Investor, Traffic barrier, Pfizer, Tropism, Partnership, Research, AAIC, Family, G&A, Therapy, Exercise, Brain, Gene expression, Senior, Company, Human, Conference, SOD1, Neurocrine Biosciences, Director, Transgene, Capsid, Telephone, Cell, Board, RNA, Neurocrine, Board of directors, Gene, U.S. Securities and Exchange Commission, AAV, Private Securities Litigation Reform Act, Patient, COVID-19, Amyotrophic lateral sclerosis, Nasdaq, Corporate Affairs, Mouse, Cardiac muscle, Antibody, Toxicity, Central nervous system, CNS, Congress, Income, GLOBE, ESGCT, European Society of Gene and Cell Therapy, Conference call, Annual report, Biomarker, D, ALS, Neurology, Pharmaceutical industry, Vaccine, Fine chemical, Lithium, IND, Novartis, Voyager

CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2022 financial and operating results.

Key Points: 
  • ET today -
    CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported third quarter 2022 financial and operating results.
  • Voyager previously received a$30 millionupfront option grant payment and, following the close of Q3 2022, received a$10 millionoption exercise payment.
  • Collaboration Revenues: Voyager had collaboration revenue of $41.1 million for the third quarter of 2022, compared to $1.5 million for the same period in 2021.
  • ET to discuss the third quarter 2022 financial and operating results.

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
Lunedì, Ottobre 31, 2022
DMD, U.S. Securities and Exchange Commission, Marketing, Safety, PMO, Diaphragm, Time, Transferrin, Clinical trial, Accelerated approval (FDA), Food, Dystrophin, Priority review, Degenerative disease, Therapy, Muscle, FSHD, Private Securities Litigation Reform Act, Heart, Second Half, Patient, SEC, Terminology, DM1, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mortality, Security (finance), FORCE, Duchenne muscular dystrophy, Disease, Company, Form 10-Q, DYN, GLOBE, Myopathy, Nasdaq, FDA, MPH, Exon, Plasma protein binding, COVID-19, Facioscapulohumeral muscular dystrophy, Review, MAD, Fast Track, Cardiac muscle, Pharmacokinetics, Pharmaceutical industry, Dyne, Facebook

WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DYNE-251 for the treatment of Duchenne muscular dystrophy (DMD) mutations amenable to exon 51 skipping. DYNE-251 is being evaluated in the Phase 1/2 DELIVER global clinical trial.

Key Points: 
  • A drug receiving Fast Track designation also may be eligible for Accelerated Approval and Priority Review if relevant criteria are met.
  • DYNE-251 is Dynes product candidate being developed for people living with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
  • Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.
  • Dyne has a broad portfolio of programs for serious muscle diseases, including candidates for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).

BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

Retrieved on: 
Venerdì, Ottobre 14, 2022
LinkedIn, Lists of diseases, Department of Neurology, Xuanwu hospital, Cardiomyopathy, Time, Congress, Drug Quality and Security Act, Disease, SEC, LVEF, Securities Exchange Act of 1934, Science, VCU, WMS, Solution, Annual report, Patient, Human, Creatine kinase, Genotype, Twitter, Virginia Commonwealth University, CK, Nasdaq, NSAD, Securities Act of 1933, Biomarker, Company, Mutation, Cardiac muscle, Poster, Neurology, FKRP, Safety, Glycosylation, Environment, GLOBE, Myopathy, Pathology, Cancer, Muscular dystrophy, Risk, Medical imaging, Pharmaceutical industry, Medical device

BridgeBio and ML Bio Solutions continue to engage with regulatory agencies and intend to initiate a Phase 3 clinical trial in 2023.

Key Points: 
  • BridgeBio and ML Bio Solutions continue to engage with regulatory agencies and intend to initiate a Phase 3 clinical trial in 2023.
  • Given impaired glycosylation of DG directly leads to the development of muscular dystrophy in LGMD2ipatients, this novel assay was designed to assess the core pathology of the disease.
  • The Phase 2 trial enrolled 14 participants, including both ambulatory and non-ambulatory patients with LGMD2i.
  • Moreover, BridgeBio operates in a very competitive and rapidly changing environment in which new risks emerge from time to time.